Direct Costs of Cervical Cancer Management in Morocco

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3159-3163

  Berraho, Mohamed ^a   Najdi, Adil ^a   Mathoulin Pelissier, Simone ^b   Salamon, Roger ^b   Nejjari, Chakib ^a  

^a Faculty of Medicine and Pharmacy   (Morocco)

^b Centre of Clinical Investigation Clinical Epidemiology   (France)

Author keywords

Cervical cancer; Health costs; Mediterranean area; Morocco; Neoplasms; Prevention

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; COST; ECONOMICS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MOROCCO; UTERINE CERVIX TUMOR;

ADULT; COSTS AND COST ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; MOROCCO; NEOPLASM STAGING; UTERINE CERVICAL NEOPLASMS;

EID: 84873593803     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3159     Document Type: Article

References (22)

1. AROME (2011). Guidelines, minimal requirements and standard of cancer care around the Mediterranean Area: Report from the Collaborative AROME (Association of Radiotherapy and Oncology of the Mediterranean Area). Crit Rev Oncol Hematol, 78, 1-16.
2. Arveux P, Bénard S, Bouée S, et al (2007). Coût de la prise en charge du cancer invasif du col de l'utérus en France. Bull Cancer, 94, 219-24.
3. El M'rini T, Arveux P, Gay C, et al (1997). Estimation du coût du traitement du cancer du col. Rev Épidémiol Santé Publique, 45, 508-15.
4. Fahs MC, Mandelblatt J, Schechter C, Muller C (1992). Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med, 117, 520-7.
5. Ferlay J, Shin H, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
6. Goldie SJ, Kim JJ, Myers E (2006). Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine, 24, 164-70.
7. Gueddari M (2001). Diagnostic précoce des cancers du sein et du col utérin. Ministère de la Santé, direction de l'épidémiologie et de lutte contre les maladies, Rabat 2001.
8. Holmes J, Hemmett L, Garfield S (2005). The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ, 6, 30-7.
9. International Agency for Research on Cancer (IARC) (2008). World cancer report.
10. Lalla Salma Association against Cancer, (2009). National Cancer Plan, Volume 3: Etude des stades de diagnostique et des résultats de traitement des cancers au Maroc.
11. Lehtinen M, Paavonen J, Wheeler CM, et al (2012). Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol, 13, 89-99.
12. Mandelblatt JS, Lawrence WF, Gaffikin L, et al (2002). Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst, 94, 1469-83.
13. Ministry of health - Morocco (2011). Santé en chiffre 2011.
14. National Cancer Institute - France (2007). Etude et Expertises: Analyse économique des coûts du cancer en France: Impact sur la qualité de vie, prévention, dépistage, soins, recherche.
15. Panorama de la santé 2007: Les indicateurs de l'OCDE. Qualité des soins. Cancer. Paris, Editions de l'OCDE, 2007, 195 p.
16. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
17. Rocconi RP, Estes JM, Leath 3rd CA, et al (2005). Management strategies for stage IB2 cervical cancer: a costeffectiveness analysis. Gynecol Oncol, 97, 387-94.
18. Sanders GD, Taira AV (2003). Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis, 9, 37-48.
19. Schaffer P, Bilger P, Allemand H (1994). L'efficacité et le coût du dépistage du cancer du col de l'utérus. Rev Med Assurance Maladie, 2, 108-20.
20. Villa LL, Costa RL, Petta CA, et al (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6, 256-7.
21. Wolstenholme JL, Whynes DK (1998). Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer, 34, 1889-93.
22. Zappa M, Cecchini S, Ciatto S, et al (1998). Measurement of the cost of screening for cervical cancer in the district of Florence, Italy. Tumori, 84, 631-5.